The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation

J. A. Bluestone, W. Liu, J. M. Yabu, Z. G. Laszik, A. Putnam, M. Belingheri, D. M. Gross, R. M. Townsend, F. Vincenti

Research output: Contribution to journalArticle

173 Citations (Scopus)

Abstract

Regulatory T cells (Treg) are critical regulators of immune tolerance. Both IL-2 and CD28-CD80/CD86 signaling are critical for CD4+CD25 +FOXP3+ Treg survival in mice. Yet, both belatacept (a second-generation CTLA-4Ig) and basiliximab (an anti-CD25 monoclonal antibody) are among the arsenal of current immunotherapies being used in kidney transplant patients. In this study, we explored the direct effect of basiliximab and belatacept on the Tregs in peripheral blood both in the short term and long term and in kidney biopsies of patients with acute rejection. We report that the combined belatacept/basiliximab therapy has no long-term effect on circulating Tregs when compared to a calcineurin inhibitor (CNI)-treated group. Moreover, belatacept-treated patients had a significantly greater number of FOXP3 + T cells in graft biopsies during acute rejection as compared to CNI-treated patients. Finally, it appears that the basiliximab caused a transient loss of both FOXP3+ and FOXP3- CD25+ T cells in the circulation in both treatment groups raising important questions about the use of this therapy in tolerance promoting therapeutic protocols.

Original languageEnglish
Pages (from-to)2086-2096
Number of pages11
JournalAmerican Journal of Transplantation
Volume8
Issue number10
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Interleukin-2 Receptors
Regulatory T-Lymphocytes
Kidney Transplantation
T-Lymphocytes
Transplants
Kidney
Biopsy
Immune Tolerance
Therapeutics
Immunotherapy
Interleukin-2
Monoclonal Antibodies
Survival
basiliximab
Abatacept
Calcineurin Inhibitors

Keywords

  • Basiliximab
  • Belatacept
  • FOXP3
  • Kidney transplantation
  • Treg

ASJC Scopus subject areas

  • Immunology

Cite this

The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. / Bluestone, J. A.; Liu, W.; Yabu, J. M.; Laszik, Z. G.; Putnam, A.; Belingheri, M.; Gross, D. M.; Townsend, R. M.; Vincenti, F.

In: American Journal of Transplantation, Vol. 8, No. 10, 10.2008, p. 2086-2096.

Research output: Contribution to journalArticle

Bluestone, J. A. ; Liu, W. ; Yabu, J. M. ; Laszik, Z. G. ; Putnam, A. ; Belingheri, M. ; Gross, D. M. ; Townsend, R. M. ; Vincenti, F. / The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. In: American Journal of Transplantation. 2008 ; Vol. 8, No. 10. pp. 2086-2096.
@article{9c2dc7d01d164a28a087a54c7c5b5ad5,
title = "The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation",
abstract = "Regulatory T cells (Treg) are critical regulators of immune tolerance. Both IL-2 and CD28-CD80/CD86 signaling are critical for CD4+CD25 +FOXP3+ Treg survival in mice. Yet, both belatacept (a second-generation CTLA-4Ig) and basiliximab (an anti-CD25 monoclonal antibody) are among the arsenal of current immunotherapies being used in kidney transplant patients. In this study, we explored the direct effect of basiliximab and belatacept on the Tregs in peripheral blood both in the short term and long term and in kidney biopsies of patients with acute rejection. We report that the combined belatacept/basiliximab therapy has no long-term effect on circulating Tregs when compared to a calcineurin inhibitor (CNI)-treated group. Moreover, belatacept-treated patients had a significantly greater number of FOXP3 + T cells in graft biopsies during acute rejection as compared to CNI-treated patients. Finally, it appears that the basiliximab caused a transient loss of both FOXP3+ and FOXP3- CD25+ T cells in the circulation in both treatment groups raising important questions about the use of this therapy in tolerance promoting therapeutic protocols.",
keywords = "Basiliximab, Belatacept, FOXP3, Kidney transplantation, Treg",
author = "Bluestone, {J. A.} and W. Liu and Yabu, {J. M.} and Laszik, {Z. G.} and A. Putnam and M. Belingheri and Gross, {D. M.} and Townsend, {R. M.} and F. Vincenti",
year = "2008",
month = "10",
doi = "10.1111/j.1600-6143.2008.02377.x",
language = "English",
volume = "8",
pages = "2086--2096",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation

AU - Bluestone, J. A.

AU - Liu, W.

AU - Yabu, J. M.

AU - Laszik, Z. G.

AU - Putnam, A.

AU - Belingheri, M.

AU - Gross, D. M.

AU - Townsend, R. M.

AU - Vincenti, F.

PY - 2008/10

Y1 - 2008/10

N2 - Regulatory T cells (Treg) are critical regulators of immune tolerance. Both IL-2 and CD28-CD80/CD86 signaling are critical for CD4+CD25 +FOXP3+ Treg survival in mice. Yet, both belatacept (a second-generation CTLA-4Ig) and basiliximab (an anti-CD25 monoclonal antibody) are among the arsenal of current immunotherapies being used in kidney transplant patients. In this study, we explored the direct effect of basiliximab and belatacept on the Tregs in peripheral blood both in the short term and long term and in kidney biopsies of patients with acute rejection. We report that the combined belatacept/basiliximab therapy has no long-term effect on circulating Tregs when compared to a calcineurin inhibitor (CNI)-treated group. Moreover, belatacept-treated patients had a significantly greater number of FOXP3 + T cells in graft biopsies during acute rejection as compared to CNI-treated patients. Finally, it appears that the basiliximab caused a transient loss of both FOXP3+ and FOXP3- CD25+ T cells in the circulation in both treatment groups raising important questions about the use of this therapy in tolerance promoting therapeutic protocols.

AB - Regulatory T cells (Treg) are critical regulators of immune tolerance. Both IL-2 and CD28-CD80/CD86 signaling are critical for CD4+CD25 +FOXP3+ Treg survival in mice. Yet, both belatacept (a second-generation CTLA-4Ig) and basiliximab (an anti-CD25 monoclonal antibody) are among the arsenal of current immunotherapies being used in kidney transplant patients. In this study, we explored the direct effect of basiliximab and belatacept on the Tregs in peripheral blood both in the short term and long term and in kidney biopsies of patients with acute rejection. We report that the combined belatacept/basiliximab therapy has no long-term effect on circulating Tregs when compared to a calcineurin inhibitor (CNI)-treated group. Moreover, belatacept-treated patients had a significantly greater number of FOXP3 + T cells in graft biopsies during acute rejection as compared to CNI-treated patients. Finally, it appears that the basiliximab caused a transient loss of both FOXP3+ and FOXP3- CD25+ T cells in the circulation in both treatment groups raising important questions about the use of this therapy in tolerance promoting therapeutic protocols.

KW - Basiliximab

KW - Belatacept

KW - FOXP3

KW - Kidney transplantation

KW - Treg

UR - http://www.scopus.com/inward/record.url?scp=51849108540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51849108540&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2008.02377.x

DO - 10.1111/j.1600-6143.2008.02377.x

M3 - Article

VL - 8

SP - 2086

EP - 2096

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 10

ER -